|
Genetic Architecture of Plasma T-PA and PAI-1 Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Genetic Architecture of Plasma T-PA and PAI-1 conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Genetic Architecture of Plasma T-PA and PAI-1 Clinical research trials and Genetic Architecture of Plasma T-PA and PAI-1 medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Genetic Architecture of Plasma T-PA and PAI-1. Genetic Architecture of Plasma T-PA and PAI-1 Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Genetic Architecture of Plasma T-PA and PAI-1 clinical trial. Subjects typically recieve the finest healthcare available for their Genetic Architecture of Plasma T-PA and PAI-1 condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Genetic Architecture of Plasma T-PA and PAI-1  Genetic Architecture of Plasma T-PA and PAI-1
Genetic Architecture of Plasma T-PA and PAI-1
For Condition: Cardiovascular Diseases,Thrombosis,Heart Diseases,Atherosclerosis
Status: No longer recruiting
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To determine the effects of six genes on thrombotic risk factors known to be associated with the development of heart disease.
Details: BACKGROUND: Abnormalities in the plasminogen activator system have been implicated in the pathogenesis of arterial and cerebral thrombosis. In particular, elevated plasma levels of plasminogen activator inhibitor-1 (PAI-1), tissue-type plasminogen activator (t-PA), and t-PA/PAI-1 complexes have been found to correlate with increased risk of myocardial infarction (MI) and/or stroke. Vascular fibrinolytic balance is, to a large part, determined by the competing effects of t-PA and PAI-1, and reflects a complex interplay between genetic and environmental factors. The present collaboration focuses on the common hypothesis that the association between activation of the renin-angiotensin-aldosterone system (RAAS) and atherothrombotic events derives from an interaction between the RAAS and the fibrinolytic system. The study is part of an initiative "Thrombosis of the Arterial and Cerebral Vasculature: New Molecular Genetic Concepts for Prevention and Treatment" which was released in April 1999. The objective of the initiative is to establish collaborative teams of closely interacting investigators with diverse, complementary areas of expertise to elucidate the molecular genetic mechanisms of thrombosis in the arterial and cerebral vasculature. DESIGN NARRATIVE: The investigators will use two population-based samples of unrelated individuals to address their aims: 1) study subjects in the PREVEND study in Groningen, The Netherlands in whom DNA and plasma samples and clinical data have already been collected and 2) an estimated 2000 unrelated study subjects from Ghana, Africa in whom data need to be collected. The collaborative study focuses on the common hypothesis that the association between activation of the renin-angiotensin-aldosterone system (RAAS) and atherothrombotic events derives from an interaction between the RAAS and the fibrinolytic system.
Eligibility:
Study Type: Observational, Natural History, Defined Population
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: No eligibility criteria
Total Enrollment:
Location and Contact Information:
Overall Study Official:
JasonMoore, , Vanderbilt University
Additional Information:
Study ID Numbers: 959;
Study Start Date: September 2000
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00007410
Other Cardiovascular Diseases Studies:
1. A Randomized Evaluation of the Effect of Routine Normal Saline Flush Versus Heparinized Saline Solution in Groshong and Groshong PICC Catheters
2. Genetic Architecture of Plasma T-PA and PAI-1
3. Heparin versus Lepirudin Flushes in Preventing Blockage of Venous Access Devices
4. Anticoagulant Therapy with Bivalirudin in the Performance of Percutaneous Coronary Intervention in patients with Heparin-Induced Thrombocytopenia (AT BAT, First Inning)
5. Lupus Cohort--Thrombotic Events and Coronary Artery Disease
Related Studies:
Other Cardiovascular Diseases Clinical Trials
Other Clinical Trials
Other Clinical Trials
Genetic Architecture of Plasma T-PA and PAI-1
|
|
|
|
|
|
|
|
